2017), CD44 (Han et al. 2015), G9a (Wei et al. 2017), NCOA5 (He et al. 2018), CXCR4 (Wang et al. 2017), Sphk1 (Cai et al. 2017), eEF2 (Pott et al. 2017), NSD1 (Zhang et al. 2019), ASPH (Iwagami et al. 2016), mir-3188 (Zhou et al. 2017), HBsAg (Song et al. 2018), MECOM (Chen et al. 2024) and HBx (Rawal n.d.), all of which impair cell proliferation and migration. Additionally, CRISPR-Cas9 has been shown to effectively downregulate BIRC5 in several cancers, providing significant therapeutic benefits (Khan et al. 2016; Albadari and Li 2023; Zhao et al. 2017; Narimani et al. 2019). Here, BIRC5 is linked to cancer.